Prasugrel: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''| [[ | '''| [[Prasugrel indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Prasugrel dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Prasugrel dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[ | '''| [[Prasugrel contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Prasugrel warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Prasugrel adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Prasugrel drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Prasugrel use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[Prasugrel overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Prasugrel description|Description]]''' | ||
'''| [[ | '''| [[Prasugrel clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Prasugrel nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[ | '''| [[Prasugrel clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Prasugrel how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[ | '''| [[Prasugrel patient counseling information|Patient Counseling Information]]''' | ||
'''| [[ | '''| [[Prasugrel labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 15:22, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Prasugrel, click here
Synonyms / Brand Names: EFFIENT®
Overview
Prasugrel is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently under clinical development in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine and clopidogrel (trade name Plavix). These agents are believed to reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors.
Category
Cardiovascular Drugs:Antiplatelet drugs
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages